Skip to main content
graph.swiss
Eli Lilly and Company

Eli Lilly and Company

955.00 CHF+30.00 (+3.24%)
XSWX:LLYMarket Closed
ListedCHF851.6BHealthcareDrug Manufacturers - General50,000 employees

Company Profile

Legal NameEli Lilly and Company
CEOMr. David A. Ricks
HeadquartersLilly Corporate Center
Phone317 276 2000
Employees (FTE)50,000
SectorHealthcare
IndustryDrug Manufacturers - General

Business Description

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. Headquartered in Indianapolis, Indiana, the company focuses on therapies addressing diabetes, oncology, immunology, neuroscience, and cardiometabolic conditions. Its portfolio includes medicines for chronic metabolic diseases, cancer treatments aimed at specific tumor types, and immunology drugs targeting inflammatory and autoimmune disorders. Eli Lilly and Company serves healthcare systems, hospitals, and pharmacies worldwide, with a strong presence in major markets such as the United States, Europe, China, and Japan. The company operates across the full pharmaceutical value chain, from research and clinical development to large-scale manufacturing and global distribution. Through its focus on innovative, science-driven therapies for complex diseases, Eli Lilly and Company plays a significant role in the healthcare sector, supporting physicians and patients with branded medicines that are integrated into standard treatment protocols across multiple therapeutic areas.

Profitability & Growth

Profitability

Profit Margin+34.99%
Operating Margin+49.39%
Return on Equity (TTM)+107.46%
Return on Assets (TTM)+20.74%

Recent Year-End

Revenue58.48B
Revenue / Share80.61
Gross Profit48.44B
EBITDA40.32B
Diluted EPS22.18
Earnings Growth YoY+168.10%
Revenue Growth YoY+55.50%

Balance Sheet Snapshot

Total Cash (MRQ)

4.28B

Total Debt (MRQ)

35.10B

Current Ratio (MRQ)

1.50

Book Value / Share

28.09

Stock Statistics

Shares Outstanding893.5M
Float Shares889.3M
Avg Volume (10d)4
Avg Volume (90d)4
% Held by Insiders+0.15%
% Held by Institutions+85.27%

Valuation

Market Cap851.61B
Enterprise Value698.44B
Trailing P/E42.61
PEG Ratio0.25
Price / Sales (TTM)11.66
Price / Book (MRQ)33.64
EV / Revenue11.94
EV / EBITDA23.83

Price Summary

52-Week Low560.00
52-Week High985.00
50-Day MA877.10
200-Day MA798.70
Beta0.51

Dividends

Forward Div Rate5.59
Forward Div Yield+0.58%
Trailing Div Rate5.22
5Y Avg Div Yield+89.00%
Payout Ratio+22.13%
Dividend Date2025-06-10
Ex-Dividend Date2026-08-14